Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells

References

• Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, Scheper RJ, van der Valk P, Leenstra S, Baayen JC, Spliet WG, Troost D. (2005). Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 46:849–857.
   PubMed Web of Science ®Google Scholar
• Audet M, Bouvier M. (2008). Insights into signaling from the β2-adrenergic receptor structure. Nat Chem Biol 4:397–403.
   PubMedGoogle Scholar
• Bain LJ, McLachlan JB, LeBlanc GA. (1997). Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ Health Perspect 105:812–818.
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM. (1995). Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68:226–239.
   PubMed Web of Science ®Google Scholar
• Bleau AM, Huse JT, Holland EC. (2009). The ABCG2 resistance network of glioblastoma. Cell Cycle 8:2936–2944.
   PubMed Web of Science ®Google Scholar
• Chan PH, Kerlan R, Fishman RA. (1982). Intracellular volume of osmotically regulated C-6 glioma cells. J Neurosci Res 8:67–72.
   PubMedGoogle Scholar
• Chang G. (2003). Multidrug resistance ABC transporters. FEBS Lett 555:102–105.
   PubMed Web of Science ®Google Scholar
• Diestra JE, Scheffer GL, Català I, Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR, Izquierdo MA. (2002). Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198:213–219.
   PubMed Web of Science ®Google Scholar
• Doshi R, Gutmann DA, Khoo YS, Fagg LA, van Veen HW. (2011). The choreography of multidrug export. Biochem Soc Trans 39:807–811.
   PubMedGoogle Scholar
• Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670.
   PubMed Web of Science ®Google Scholar
• Garimella TS, Ross DD, Bauer KS. (2004). Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 807:203–208.
   PubMed Web of Science ®Google Scholar
• Ishikawa T. (2009). The role of human ABC transporter ABCG2 (BCRP) in pharmacotherapy. Adv Drug Deliv Rev 61:1–2.
   PubMedGoogle Scholar
• Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, Sugiyama Y. (2004). Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21:1895–1903.
   PubMed Web of Science ®Google Scholar
• Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R. (2007). Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 24:1262–1274.
   PubMedGoogle Scholar
• Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G, Peters GJ. (2009). Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer 100:1120–1127.
   PubMed Web of Science ®Google Scholar
• Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. (2001). Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458–3464.
   PubMed Web of Science ®Google Scholar
• Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. (2009). Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28:2358–2363.
   PubMed Web of Science ®Google Scholar
• Minderman H, Suvannasankha A, O’Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR. (2002). Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59–65.
   PubMedGoogle Scholar
• Moitra K, Lou H, Dean M. (2011). Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491–502.
   PubMed Web of Science ®Google Scholar
• Nardozzi JD, Lott K, Cingolani G. (2010). Phosphorylation meets nuclear import: a review. Cell Commun Signal 8:32.
   PubMed Web of Science ®Google Scholar
• Ni Z, Bikadi Z, Rosenberg MF, Mao Q. (2010). Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 11:603–617.
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47–50.
   PubMed Web of Science ®Google Scholar
• Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE. (2009). ABCG2: a perspective. Adv Drug Deliv Rev 61:3–13.
   PubMed Web of Science ®Google Scholar
• Salacz ME, Watson KR, Schomas DA. (2011). Glioblastoma: Part I. Current state of affairs. Mo Med 108:187–194.
   PubMedGoogle Scholar
• Solazzo M, Fantappiè O, D’Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R. (2009). Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res 69:7235–7242.
   PubMed Web of Science ®Google Scholar
• Takada T, Suzuki H, Gotoh Y, Sugiyama Y. (2005). Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 33:905–909.
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Beijnen JH. (2003). P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 89:1776–1782.
   PubMed Web of Science ®Google Scholar
• Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. (2002). Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035–5040.
   PubMed Web of Science ®Google Scholar
• Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave ME, Qiu Y. (2008). The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283:3349–3356.
   PubMed Web of Science ®Google Scholar
• Yeboah D, Kalabis GM, Sun M, Ou RC, Matthews SG, Gibb W. (2008). Expression and localisation of breast cancer resistance protein (BCRP) in human fetal membranes and decidua and the influence of labour at term. Reprod Fertil Dev 20:328–334.
   PubMed Web of Science ®Google Scholar